Compare Teucrium Soybean Fund (SOYB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teucrium Soybean Fund vs Tango Therapeutics Inc. — how do they compare? Teucrium Soybean Fund trades at $27.2 (market cap $43.28M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 86.6× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teucrium Soybean Fund for 25 Days and Tango Therapeutics Inc. for 0 Days on average.
| SOYB | TNGX | |
|---|---|---|
Market Cap | $43.28M | $3.75B |
Volume | 28,719 | 9,619,106 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $28.14 | $32.90 |
52-Week Low | $21.59 | $7.50 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOYB trades at $27.33, down 0.51% today, with a bullish technical signal driven by moving averages. The stock is consolidating near key support at $27, with neutral oscillators indicating limited momentum. Recent news highlights potential catalysts from U.S.-China trade talks, which could boost soybean demand.
The outlook hinges on trade developments and commodity price trends, offering upside if diplomatic progress materializes. Risks include geopolitical tensions and commodity market volatility. Analyst sentiment appears cautiously optimistic, but fundamental data remains sparse for detailed assessment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
